SUSTAIN (A Phase II, Multicenter, Randomized, Placebo-Controlled, Double-Blind, 12-Month Study to Assess Safety and Efficacy of SEIGI With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients with Sickle Cell-Related Pain Crises
Clinical Trial Grant
Administered By
Medicine, Hematology
Awarded By
Selexys Pharmaceuticals, Corp
Start Date
February 1, 2014
End Date
January 31, 2017
Administered By
Medicine, Hematology
Awarded By
Selexys Pharmaceuticals, Corp
Start Date
February 1, 2014
End Date
January 31, 2017